VTI Launches InterGraft Biologics

Vertebral Technologies Inc. (VTI), has launched InterGraft, a series of human osteobiologics that adds regenerative medicine to the repertoire of VTI’s spinal products.
 
VTI’s InterGraft series features osteoinductive and wound care scaffolds to aid in implantation and overall surgical success. This includes Matrix OI, demineralized bone matrix in various forms such as strips, blocks, crunch, and putty, each containing all five bone-forming elements (chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone) to optimize bone growth and fusion.
 
“When surgeons are performing spinal procedures and are concerned for their patients’ health, the biologics that are used to aid the healing process are essential to a successful fusion. VTI is proud to supply regenerative osteobiologics to accompany our modular spinal implants. Our concern is with patients’ recovery and increased mobility, and with surgeons’ ability to access the products needed for a successful procedure,” said Matt Kyle, president and CEO of VTI.
 
The InterGraft biologics are 100 percent demineralized bone matrix percentage by weight, have pliable bone morphogenetic proteins that is a containment scaffold for stem cells, are processed aseptically using the proprietary BioRinse sterilization technology, and is in accordance with American Association of Tissue Banks standards and U.S. Food and Drug Administration regulations.
 
Vertebral Technologies Inc. is a privately held company based in Minnetonka, Minn. VTI designs, develops, manufactures and markets medical devices that address painful conditions of the spine through less-invasive surgical approaches. Founded in 2005, VTI’s products utilize its unique modular-assembly technology to deliver solutions optimized for both surgeons and their patients. VTI has sold more than 7,000 InterFuse modular interbody fusion devices worldwide to date.

Watch the video below to learn more about VTI’s surgical technique: